Jacobson Pharma Corporation Limited (HK:2633) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jacobson Pharma Corporation Limited reported a robust financial performance for the six months ending September 2024, with a 13.3% increase in revenue to HK$810.0 million and a 44.2% surge in profit from continuing operations to HK$140.3 million. The company also declared a 40% higher interim dividend, reflecting strong growth compared to the same period in 2023. These results highlight the company’s resilient business model and its promising outlook for investors.
For further insights into HK:2633 stock, check out TipRanks’ Stock Analysis page.